Clinical Trial Detail

NCT ID NCT01217931
Title Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

kidney cancer

Therapies

Everolimus

Pazopanib

Bevacizumab

Age Groups: senior adult

No variant requirements are available.